Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?

Amgen and Gilead Sciences are compared as dividend-paying biotech stocks. Amgen offers a higher yield (2.2%) and stronger product sales growth, while Gilead has a lower payout ratio (43.5% vs 60.9%) and better valuation metrics. The choice depends on investor priorities: Amgen suits yield-focused investors, while Gilead appeals to those prioritizing safety and value. Both stocks offer higher yields than the S&P 500.